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Terasaki's Seminal Contributions 
in HlA and Organ Transplantation 
Thomas E. Starzl. MD. PhD 
A LL OF US HAVE heroes. Paul Terasaki is one of mine. not only because of what he has achieved in life. but 
because of how he has done it. More than a half cen-
tury ago, the Terasaki boy was peering out through the fence 
of a concentration camp where he and other loyal Americans 
of Japanese ancestry had been unjustly imprisoned during 
World War II. Yet. from this unfriendly soil grew the man who 
today is the recipient of the Emily Cooley Memorial Award of 
the American Association of Blood Banks. 
The Terasaki Record 
The list of Terasaki's innovative contributions is extensive 
(Table 3-1). It is noteworthy that these were all linked in one 
way or other to the microcytotoxicity test. with which anti-
body reactivity against human lymphocytes and other cells 
can be detected.! The observations and clinical applications 
made possible with this technology elevated Terasaki to a 
leadership position in multiple areas that were essential for 
the orderly advance of organ and marrow transplantation. 
His accomplishments include: 1) development of the 
cytotoxiC crossmatch2 and panel reactive antibody tests3 
Thomas E. Starzl. MD. PhD. Director oJTransplant Institute. Medical Center. 
University oj Pittsburgh. Pittsburgh. Pennsylvania 
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Table 3-1. Paul Terasaki Landmarks 
Event 
Microdroplet assay for human serum cytotoxins 
Cytotoxic cross match for transplantation 
Panel reactive antibody for detecting presensitization 
Discovery of new HLA antigens 
Discovery of HLA and disease associations 
First prospective trial in transplantation of HLA matching 
Collinsrrerasaki solution for organ preservation 
Epidemiologic investigation of survival factors with 
transplantation 
Guidelines for organ sharing 
The blood transfusion effect on allograft survival 
Discovery of natural killer cells 
Date 
1964 
1965 
1971 
1965-present 
1972-present 
1966 
1969 
196B-present 
1969-present 
1973 
1973 
used universally today to detect recipient presensitization to 
donor tissues. 2) the detection of new HLA antigens and their 
disease associations. 3) the first use of tissue (HLA) matching 
as the basiS of donor selection for tissue and organ trans-
plantation. 4 4) efficient techniques of organ preservation (be-
ginning with the Collins/Terasaki solution) that allowed time 
for HLA typing. 5 5) epidemiologic investigation of the effect of 
biologic variables and different therapies on transplantation 
outcome.6 .7 6) discovery of the beneficial effect of blood trans-
fusions on kidney allograft survival. B and 7) contributions to 
network development for organ sharing. The ripple effects of 
this work have. of course. extended into blood bank practices 
and clinical medicine far beyond the boundaries of trans-
plantation. and have inspired numerous initiatives. 
Some of Terasaki's discoveries have not received due 
credit. in part because of his disinterest in pursuing priority 
claims. For the record. however. it was he and his associates 
who discovered the presence of lymphocytes in normal 
nonimmunized persons that killed a wide range of cultured 
tumor cells. but were not tumor-specifIc. 9 . 1O These were the 
natural killer (NK) cells more completely delineated and pop-
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ularized bv workers at the American National Cancer Insti-
tute, III:! in- Sweden. 14. 15 and elsewhere. In addition, Terasaki's 
recognition of hyperacute rejection by preformed host 
antigraft cytotoxins and his introduction of the crossmatch 
test to prevent this complication2 have often been attributed 
to Kissmeyer-Nielsen of Denmark. IS 
An American Parallel to the Lysenko Mfair 
In contrast to his indifference to personal credit. Terasakfs 
integrity in promptly and accurately presenting clinically rel-
evant data is legendary. This scrupulousness led to events 
not unlike those of the Lysenko Affair. Many readers will re-
call Professor Trofim D. Lysenko. a geneticist who controlled 
research resources in the Soviet Union before and after World 
War II. aided by personal support from Josef Stalin. 17 
From this administrative power base. Lysenko was able to 
stifle opposition to his views on genetics which. as it turned 
out, were naive and wrong. Lysenko eventually was fired in 
1964 after efforts to improve farm crops with his methods 
came to a disastrous end. 18 However. his reign of scientific 
terror had eliminated reinforcement of the genetiCS talent 
pool in the Soviet Union for more than 20 years. with an after-
math that remains a national tragedy. 19 
The analogy to Terasaki's difficulties is readily apparent. 
Terasaki's "offense." like that of scientists who were crushed 
by Lysenko. was to make observations that did not conform 
to bureaucratic expectations. His peers (and Terasaki him-
selO had predicted that the development of clinical trans-
plantation would hinge on identifying gradations of the HLA 
match between the donor and reCipient. 
The critical need for HLA matching in marrow transplanta-
tion was promptly and unequivocally verified. Infusion of 
anything less than perfectly or near perfectly matched donor 
marrow resulted in a high rate of graft-vs-host disease 
(GVHD) or else rejection of the graft. This was the explicit 
message in the report of the first successful human marrow 
transplantation by Meuwissen. Gatti. Terasaki. Hong. and 
Good entitled "Treatment of lymphopenic hypogammaglob-
ulinemia and bone-marrow aplasia by transplantation of 
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allogeneic marrow: Crucial role of histocompatibility match-
ing.,,20 
Paradoxically. tissue matching proved not to be critical for 
successful transplantation of the kidney or any other organ. 
Terasaki documented this. first in cases of live donor kidney 
transplantation2 1.22 and subsequently in cases of cadaver kid-
ney transplantation. 23 In both studies. the degree of HLA 
match had little influence on clinical outcome unless the 
match was perfect or near perfect (ie. a zero-antigen mis-
match). This was ultimately verified with other kinds of organ 
transplantation. 
The seemingly opposite conclusions about the crucial role 
of HLA matching for marrow but not for organ transplanta-
tion were both correct. Very little has been added to 
Terasaki's controversial kidney transplant observations of 
three decades ago. as illustrated by two more recent publica-
tions. One report describes a multicenter study of kidney 
transplantation in which equivalent results were obtained 
with transplantation of kidneys from randomly matched live 
unrelated donors (eg. spouses) and kidneys from one 
haplotype matched (eg. parental) related donors. In both re-
lated and unrelated donor cases. there was no demonstrable 
survival advantage unless there was a zero-antigen mis-
match. 24 
The other report describes a study of more than 31. 000 
first-time recipients of cadaver kidneys entered into the 
United Network for Organ Sharing (UNOS) registry between 
1991 and 1995.25 Although optimal matches had been sought 
prospectively. zero-antigen mismatched kidneys had been 
found for only about 7% of the patients: this small cohort had 
a significant survival advantage. It was noteworthy that the 
survival curves of the HLA-incompatible cadaver kidneys 
were surprisingly close to the zero-antigen mismatched or-
gans. ApprOximately 85% of the patients received kidneys 
mismatched for two to five antigens. In this mismatch range. 
the 1- and 3-year graft survival was bracketed within less 
than a 5% spectrum. Half-life projections of kidneys surviv-
ing 1 year were in the narrow spread of 9-11 years (Fig 3-1. 
left).25 An independent analysis of 1780 cadaver cases 
showed the same lack of a stepwise matching effect. although 
there was an equal survival advantage for zero-antigen mis-
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Figure 3-1. The influence of zero·antlgen to six-antigen HLA mismatches on the 1- and 
3-year survival and the "half·life" of first cadaver kidney allografts. Left: UNOS experience 
1991-95 (n = 31,291) exclusive of Pittsburgh cases. Right: Pittsburgh experience 1981-95 
(n = 1780). Data from Starzl et al.25 
matched kidneys and for kidneys mismatched for a single 
HLA antigen (Fig 3-1. right).25 
The foregoing results were remarkably similar to those 
published by Terasaki between 1969 and 1971. Yet. his early 
reports were treated as a scientific scandal. 261p1561.27 The re-
sponse of the medical establishment was swift and severe. 
Within a few weeks after he presented his results to the Inter-
national Transplantation Society at The Hague in September 
of 1970.22.23 an emergency site visit was made to Terasaki's 
laboratory by National Institutes of Health (NIH) authorities 
and their scientific advisors. In an unprecedented exercise of 
bureaucratic power. his research contract was canceled, 
leaving him without financial support. 
When he later was proved to have been correct, Terasaki 
emerged as the father of clinical HLA matching and as an en-
during symbol of integrity. Extrapolation of his impeccably 
documented conclusions about HLA matching for organ 
transplantation breathed life into the still struggling fields of 
liver. heart, and lung transplantation where most candidates 
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could not wait for a well-matched donor. It was a relief to 
know that the use of randomlv matched donors was not going 
to result in an intolerable pe~altyKOT 
The One-Way Paradigm 
Why was it that tissue typing was not essential for the evolu-
tion of clinical organ transplantation. but was a prerequisite 
for successful marrow transplantation? The answer can be 
fully understood only by peeling back the layers of history. 
The dawn of modern transplantation immunology usually is 
set during World War II. with the demonstration by Peter 
Medawar (a zoologist) and Thomas Gibson (a plastic surgeon) 
that rejection is an immune response. 28.29 
Their research had been stimulated by the proposed use of 
skin allografts from cadaver donors for the treatment of fire 
bomb victims during the Battle of Britain. Because allografts 
were invariably rejected. they were perceived from the begin-
ning as defenseless islands in a hostile recipient sea: ie. the 
targets of a one-way host-vs-graft (HVG) immune reaction 
(Fig 3-2. upper left. shown with a kidney). This was the un-
challenged paradigm of transplantation immunology for the 
next half century. It probably remains the mental image of 
most people today. 
This concept was reinforced in 1953 when it was demon-
strated in mice by Billingham. Brent. and Medawar that tol-
erance to allogeneic leukocytes could be acqUired. In the orig-
inal experimental model. 30.31 the engraftment of adult spleen 
or marrow cells depended on the inability of the immature 
immune system of neonatal mouse reCipients to reject the 
allogeneic cells. Subsequently. an analogous immunologi-
cally defenseless state was produced in adult mouse reCipi-
ents by destrOying their immune system with supralethal to-
tal body irradiation. 32.33 If the donor immune cells engrafted 
(Fig 3-2. upper right) the reCipients in later life could accept 
skin or other tissues and organs from the original donor 
strain. but not from other strains. 
However. it was soon learned in the mouse experiments. 34.35 
and later confirmed in large animals and humans. that the 
hematolymphopoietic graft would turn the tables on the re-
cipient unless there was a perfect or near perfect 
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Figure 3-2. Top panels. Historical conception of transplantation immunology in terms of a 
unidirectional immune transaction: (left) host-vs-graft (HVG) reaction with whole organs 
and (right) graft-vs-host (GVH) reaction with marrow or other hematolymphopoietic trans-
plants. Bottom panels. Correct view of transplantation as a bidirectional and mutually can-
celing immune reaction that is (left) predominantly HVG with whole organ grafts. and (right) 
predominantly GVH with marrow grafts. The bone silhouette in the kidney (bottom left) con-
notes the "passenger leukocytes" of marrow origin that are constituents of all organs. 
histocompatibility match. The clinical result was the dreaded 
graft-vs-host (GVH) reaction. These observations were inter-
preted in the same "defenseless island in a hostile sea" con-
text as organ transplantation. but in mirror image (ie. now 
the graft rejected the host). As with the simplistic view of or-
gan transplantation (Fig 3-2. upper right). this was a concep-
tual error. Nevertheless. the demonstration that tolerance 
could be acquired and was associated with donor leukocyte 
chimerism was a seminal turning pOint. It ultimately led in a 
straight line to the clinical field of marrow transplan-
tation.36-40 
The second turning point in transplantation immunology oc-
curred in the early 1960s. This was the demonstration that or-
gan allografts could "self-induce" tolerance. if they were trans-
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planted under an umbrella of immunosuppression.' i This 
discovery galvanized a revolution in clinical organ transplanta-
tion. The downside, however. was the erroneous conclusion 
that engraftment of organs (turning point 2) occurred by differ-
ent mechanisms than the leukocyte chimerism dependent 
engraftment of spleen or marrow cells (turning point 1). 
The striking disparities between marrow and organ trans-
plantation (Table 3-2) seemed too great to permit any other 
conclusion. The clinical differences were: 1) dependence on 
or independence from HLA matching for successful trans-
plantation. 2) risk vs freedom of risk from GVHD. and 3) fre-
quent vs infrequent achievement of drug-free status after 
transplantation. The semantic distinction between the "toler-
ance" of marrow transplantation and the "acceptance" of or-
gan grafts reflected the assumption that engraftment in-
volved different mechanisms. 
Thus. although the original seed of transplantation was 
universally conceded to be Medawar's demonstration that re-
jection was an immune event. it was thought for many years 
that the seed had given root to fundamentally unrelated clini-
cal trees (Fig 3-3). As it turned out. all of the differences were 
explained by cytoablation of the marrow recipient but not of 
the organ recipient. How this came to be recognized, along 
with an explanation of Terasaki's heretical observations 
about the role of HLA matching for both kinds of transplanta-
tion' is the focus of the following sections. 
Table 3-2. Differences between Organ and Marrow Transplantation 
Organ Marrow 
Feature Transplantation Transplantation 
Host cytoablation No Yes' 
HLA matching Not critical Critical 
Principal complication Rejection Graft-vs-host disease 
I mmu nosuppression-free Uncommon Common 
Term for success Acceptance Tolerance 
"This therapeutic step allows a relatively unopposed graft-vs-host reaction and accounts for 
the other differences. 
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Solid Organ Bone Marrow 
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Acceptance --+H!:l!!!--- Graft Take ---tgK~-- Tolerance 
Uncommon _-Pl-J!II.\I---- GVHD 
(Medawar) 
Figure 3-3. The division of transplantation into two separate disciplines, caused by different 
treatment policies. 
The Empirical Development of 
Organ Transplantation 
While clinical marrow transplantation was a logical exten-
sion of the neonatal tolerance model. organ transplantation 
appeared to be disconnected from a rational scientific base. 
The intellectual handicap notwithstanding. whole organ 
transplantation was successfully performed in humans 
nearly 10 years before this was first achieved unequivocally 
with marrow. Between January 1959 and March 1963. 
Merrill and Murray in Boston.42 and then the French teams of 
Hamburger3 .44 and KUSS -l5 produced six clinical examples of 
kidney allograft survival exceeding 6 months after 
pretreating their uremic patients with sublethal total body ir-
radiation. but without inJusion oj donor marrow (Table 3-3). 
The first two recipients. whose donors were fraternal twins. 
survived with good renal function for more than 20 years. 
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Table 3-3. Kidney Transplant Recipients Surviving ~ 6 Months 
as of March 1963 
Survival 
Patient Reference Surgery Date Donor (months)· 
1 42,46 1-24-59 Frat twin >50 
2 43,44 6-29-59 Frat twin >45 
3 45 6-22-60 Unrelated' 18 (Died) 
4 43 12-19-60 Mother! 12 (Died) 
5 45 3-12-61 Unrelated! 18 (Died) 
6 44 2-12-62 CousinT >13 
7 46,47 4-5-62 Unrelated 10 
*The kidneys in patients 1,2, and 6 functioned for 20.5,25, and 15 years, respectively. Pa-
tient 7 rejected his graft after 17 months and died after return to dialysis. 
t Adjunct steroid therapy. 
Pretreatment of the recipient with irradiation was too im-
practical and dangerous for general use. Consequently, these 
few successes were exceptions in a sea offailures. However, a 
seventh kidney recipient (Table 3-3) survived almost 1 year 
after transplantation: he had been treated from the time of 
surgery with the 6-mercaptopurine analogue. azathioprine. 47 
It had been learned by this time that for more than an occa-
sional success in either dogs or humans. azathioprine 
needed a partner drug. This proved to be prednisone. 
It was known from canine kidney and liver transplant 
studies at the University of Colorado that prednisone could 
reverse 90% of the rejections developing under azathioprine. 
With this information, the clinical kidney transplant pro-
gram in Denver was begun in the autumn of 1962, combining 
azathioprine with dose-maneuverable prednisone. Eight of 
the first 10 recipients had prolonged kidney allograft sur-
vival41 including two who still bear the longest continuously 
functioning allografts in the world after more than 36 years. 
As had been expected, rejection was regularly reverSible. 
Far more important, the transplanted kidneys appeared to 
have self-induced variable donor-specific tolerance. Both ob-
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servations were capsulized in the title of the report of this ex-
perience: "The reversal of rejection in human renal homo-
grafts with subsequent development of homograft 
tolerance ... 41 The best evidence of tolerance was the diminish-
ing need for maintenance immunosuppression following suc-
cessful reversal of rejection (Fig 3-4). The nonreactivity was 
donor-specific enough to allow many patients to go home to 
an unrestricted environment within a few weeks. Eventually. 
the tolerance was shown in some patients to be independent 
of immunosuppression. 40 These same posttransplant events 
of an immunologic confrontation and resolution were ulti-
mately demonstrated with liver,49 heart. lung, and pancreas 
transplantation. 
Ten (22%) of the first 46 recipients of living related donor 
kidneys in the original Colorado series still have functioning 
original allografts. 35 to nearly 37 years later. Five of the 10 
recipients have been drug-free for 6 to 33 years. By October 
1995. the cumulative time of these patients off drugs already 
equaled the time on treatment (Fig 3-5). Four more years 
have now passed. Although two received HLA-identical allo-
grafts. two received one-haplotype mismatched kidneys (sec-
ond and bottom bars), and one received a completely mis-
matched kidney from a great aunt (second bar from bottom). 
The liver has been the most tolerogenic organ. 49,50 Among 
the 42 longest surviving cadaveric liver reCipients at the 
Immune 
Reaction 
Time After Transplantation 
Figure 3-4. Historical view of events after successful organ transplantation: rejection, its re-
versal and the development of donor-specific nonreactivity." 
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patients whose renal allografts had functioned continuously since their transplantation in 
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Figure 3-6. Time on and off immunosuppression of 12 long-term surviving liver recipients 
who were free of drug treatment in October 1995. Patients 150 and 169 stopped their medi-
cation less than 2 years after transplantation because of noncompliance. The others were 
weaned because of complications of chronic immunosuppression. After 3-112 more years. 
these 12 patients remain drug-free. Data from Starzl et al.·' 
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Universities of Colorado and Pittsburgh. now 18 to 30 years 
after their transplantation. 20 (nearly halfl have been 
drug-free for I to 20 years. For the first 12 recipients to come 
off drugs. the cumulative time off immunosuppression as of 
1996 already had exceeded the time on treatment (Fig 3-6). 
These observations showed the feasibility of organ trans-
plantation and defined a formulaic management strategy 
(Table 3-4) that was applicable to all organs. However. the 
early loss of both grafts and patients remained so high for an-
other 13 years that cadaver organ transplantation (even of 
the kidney) remained controversial until the advent of 
cyclosporine in 1979. 5153 Ten years later. further improve-
ments were made possible with the introduction of 
tacrolimus. 54' 56 Thus. the improvement with transplantation 
of the kidney, liver, and all other organs has occurred in three 
distinct drug-defined rather than HLA-defined eras. 
The liver graft and patient survival curves shown in Fig 3-7 
illustrate the azathioprine-, cyclosporine-. and tacrolimus-
based treatment eras. Because retransplantation became in-
creasingly more reliable with the more potent agents. patient 
survival was better than graft survival. With the advent of 
tacrolimus. which was the first immunosuppressant to be 
evaluated primarily with liver transplantation. intestinal 
transplantation finally became a viable clinical option in the 
1990s.,,7 
Table 3-4. Empirical Therapeutic Dogma of Immunosuppression 
Ingredients of Strategy 
Baseline therapy 
Secondary adjustments of prednisone 
dose, or antilymphoid agents; 
Case-to-case trial (and potential error) 
of weaning 
Baseline Agents 
Azathioprine' 
Cyclosporine 
Tacrolimus 
• Alone or with prophylactic prednisone. EqUivalent results were obtained With cyclophos· 
phamlde instead of azathioprine. 
'Initially used for prophylactic "induction," 
~~ __ ,._.,......J-_0C_'_' ___ ~_""_K~ ___ ' __ --_· __ 
---_._---
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Figure 3-7. The three eras of orthotopIC liver transplantation at the Universities of Colorado 
(1963-80) and Pittsburgh (1981-1993). defined by azathioprine-. cyclosponne-, and 
tacrolimus-based immune suppression. Similar but less dramatic stepwise improvement 
has been seen with all organs. Patient survival was about 10% higher than graft survival in 
both the cyclosporme (1980-89) and tacrolimus eras (1989-93) because of effective 
retransplantation. an optIOn that. tor all practical purposes. did not eXist with 
azathioprme-based therapy. 
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The Discovery of Occult Chimerism 
in Organ Recipients 
Despite the diversity of the immunosuppressants. the basic 
pattern of convalescence shown in Fig 3-4 remained the 
same with all the drugs and for all transplanted organs. Or-
gan graft acceptance could be achieved with individualized 
dose adjustments of the increasingly potent drugs. guided by 
evidence or lack of evidence of rejection (Table 3-4). But what 
was being accomplished with this strategy? 
When the answer came in 1992. it provided an explanation 
for the enigmatic lack of effect of HLA matching in organ 
transplantation first documented by Terasaki. Until then. it 
had been thought that the highly antigenic tissue leukocytes 
of marrow origin. which are a component of all tissue and or-
gan allografts (Fig 3-2. bottom left and Fig 3-8. left. shown as 
a bone silhouette). were "the enemy" of engraftment. The as-
sumption was that these "passenger leukocytes" had to be 
destroyed by the host immune system as a prerequisite for 
successful organ transplantation with selective sparing of 
the speCialized parenchymal cells (Fig 3-8. right). 
Organs: The One Way Paradigm 
_ Successful ..... 
, ... , ____ ~ Engraftment 
o Non Parenchymal ~ Parenchymal 
Figure 3-8. Conventional view of a successfully transplanted allograft in which the 
non parenchymal white cells (passenger leukocytes) are depicted on left as a bone 
Silhouette. These donor cells were assumed to have been destroyed by the host immune sys-
tem (silhouette absent on right). 
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In 1992. we asked an obvious question. surprisingly for the 
first time: had these donor leukocytes really been destroyed. 
or had they merely migrated into the recipient with survival of 
their progeny? To obtain the answer. 30 long-term surviving 
liver and kidney recipients with functioning allografts were 
restudied 10-30 years after transplantation. In addition to 
blood samples. open biopsies were obtained of the trans-
planted organs. the recipient lymph nodes and skin. and 
when indicated. other host organs (eg. the heart. intestine. 
and marrow). 
Small numbers of donor leukocytes were found in the host 
peripheral tissues or blood of all 30 patients. 50.58.59 The donor 
leukocyte chimerism. including donor dendritic cells. was 
demonstrated with immunocytochemical methods. and con-
firmed with polymerase chain reaction studies. With this in-
formation. it was deduced that organ transplantation in-
volved a double immune reaction. which had both an HVG 
response (rejection) and a covert GVH response (Fig 3-9). Fol-
lowing organ transplantation. the dominant host system 
usually rejects the graft. However. serious or lethal GVHD is 
not rare after transplantation of leukocyte-rich organs such 
as the liver. ,OliO 
Failure 
Immune I ~~ __________ ~~~~~~~;;K~~~~ Reaction "" Success GVH 
...... Failure 
Time after Transplantation 
Figure 3-9. Contemporaneous HVG and GVH reactions that occur after transplantation. 
Treatment failure IS defined as the inability to control one of the reactIOns, or sometimes 
both. Acute reciprocal clonal exhaustion after successful transplantation IS maintained sub' 
sequently by chlmerlsm·dependent low-grade stimulation of both leukocyte populations 
that may wax and wane. (Used with permission from Ramsey et al. e') 
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The critical events of allograft acceptance (and tolerance) 
were postulated to be the early ones. involving the seminal 
mechanism of" ... [widespread] responses of co-existing do-
nor and recipient immune cells. each to the other. causing re-
ciprocal clonal expansion. followed by peripheral clonal dele-
tion. ,,50.58 The unusual tolerogenicity of the liver was 
explained by its large content of leukocytes. but the same 
mechanisms apply in varying degrees with transplantation of 
all organized tissues and organs. 
By 1998. compelling evidence confirming this concept had 
accumulated from controlled animal experiments. 61 Organ as 
well as marrow "acceptance" were related forms of 
chimerism-dependent acquired tolerance-not fundamen-
tally different from the major histocompatibility complex 
(MHC)-restricted antigen-specific tolerance induced by 
non cytopathic microorganisms6H4 but made more complex 
by the presence of the double immune reaction and by the ad-
ditional factor of immunosuppression. 61 The four interrelated 
events shown in Fig 3-10 must occur in close temporal prox-
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Figure 3·1 o. The four events that occur In close temporal proxlmatlon when there IS success-
ful organ engraftment: above. double acute clonal exhaustion (numbered 1 and 2) and sub-
sequent maintenance clonal exhaustion (3) plus. below. loss of organ Immunogenlclty due 
to reduction of the graft's passenger leukocytes (4) (Used with permission from Starzl et 
aL") 
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imity for successful organ engraftment: double acute clonal 
expansion and deletion. maintenance of the waxing and wan-
ing clonal exhaustion. and loss of organ immunogenicity as 
the passenger leukocytes depart from the graft. The only 
mechanisms required were clonal activation and deletion. 
and an ancillary mechanism of "immune indifference." both 
regulated by the migration and localization of the donor leu-
kocytes. 51 
With the double immune reaction. and induction of allo-
specific nonreactivity (each cell population to the other). it 
was easy to understand how the expected HLA-matching in-
fluence was "blindfolded" as Terasaki's early studies had 
suggested. With each further level of histoincompatibility. 
the resulting nullification effect escalates both ways. provid-
ing the process occurs under an umbrella of immunosup-
pression that affects both cell populations equally (Fig 3-11). 
A serious tilt in one direction defines GVHD. With an uncon-
trolled imbalance in the other direction. the consequence is 
rejection. 
With host cytoablation. as is carried out in preparation for 
conventional marrow transplantation. the tilt favoring the 
immunocompetent graft leukocytes is so extreme that GVHD 
is the most common complication (Fig 3-12. bottom). This 
can be controlled or avoided only with the use of HLA-
matched donors (Fig 3-12. top) as was recognized in 
Terasaki's earliest collaboration with doodK~o The nullifica-
tion effect also explains why GVHD is so uncommon after or-
gan transplantation. even of leukocyte-rich organs such as 
the liver and intestine. and why it is safe to infuse adjunct do-
nor marrow in organ reCipients. providing the patients are 
not immunologically weakened in advance by cytoablation or 
other means.'K 
In fact. conventional marrow transplantation is in princi-
ple a mirror image of organ transplantation. and also gov-
erned by antigen migration and localization (Fig 3-2. bottom 
right). The host leukocytes are not all eliminated by pretrans-
plant cytoablation as has been proved by Przepiorka and 
Thomas et al.titiThe weak HVG reaction mounted by those re-
maining reCipient cells. and the parallel GVH reaction of the 
dominant population of donor cells can eventually result in 
reciprocal tolerance. 
----_.---_ .•. - ... 
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Mutual Natural 
Immunosuppression 
Figure 3-11. The reciprocal immune reaction that occurs with increasing intensity in propor-
tion to HLA mismatch following organ transplantation to a noncytoablated recipient. The 
nullification effect of the donor and recipient cell population "blindfolds" the HLA mismatch-
ing effect. 
The Terasaki Legacy 
The Terasaki record summarized in Table 3-1 falls short of 
characterizing the Terasaki legacy. Looking back through 
defogged lenses. we are able to see the signiflcance of what 
Terasaki accurately recorded decades ago from his studies of 
kidney transplant recipients. Far from a scandal. it was a key 
discovery that eventually was Critical in uncovering the true 
meaning of allograft acceptance. acquired tolerance. and. in 
fact. the essence of self/nonself discrimination. 
At a Critical time. Terasaki separated himself from col-
leagues who were seduced by the power of anticipation. As a 
consequence. he was pilloried at tlrst. then vindicated. and 
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Match 
Mismatch 
Figure 3-12. Explanation for uncontrollability of GVHD with MHC-mismatched donors when 
the mutual cell engagement shown in Fig 3-11 is prevented by host cytoablation (ie, in prepa-
ration for marrow transplantation). 
ultimately honored. In between times. so many years had 
passed that it no longer really mattered. When the smoke 
cleared. we were left in the end with Paul Terasaki. the 
prototypical scientist described in the 19th century by 
Claude Bernard. the father of experimental medicine: 
"There are. indeed. two sides to science in evolution: on 
the one hand. what is known already. and on the other 
hand. what remains to be acquired. In the already ac-
quired. all men are more or less equal. and the great can-
not be distinguished from the rest. Mediocre men often 
have the most acquired knowledge. It is in the darker re-
gions of science that great men are recognized: they are 
marked by ideas which light up phenomena hitherto ob-
scure and carry science forward.""? 
TERASAKI'S SEMINAL CONTRIBUTIONS 51 
References 
1. Terasaki PI. McClelland JD. Microdroplet assay of hu-
man serum cytotoxins. Nature 1964;204:998. 
2. Terasaki PI. Marchioro TL. Starzl TE. Sero-typing ofhu-
man lymphocyte antigens: Preliminary trials on long-
term kidney homograft survivors. In: Histocompatibility 
testing. Washington. DC: National Academy of Science/ 
National Research Council. 1965:83-96. 
3. Terasaki PI. Mickey MR. Kreisler M. Pre sensitization and 
kidney transplant failures. Postgrad Med J 1971;47: 
89-100. 
4. Terasaki PI. Vredevoe DL. Mickey MR. et al. Serotyping 
for homotransplantation. VI. Selection of kidney donors 
for thirty-two recipients. Ann NY Acad Sci 1966: 129: 
500-20. 
5. Collins GM. Bravo-Shugarman M. Terasaki PI. Kidney 
preservation for transportations. Initial perfusion and 
30-hours' ice storage. Lancet 1969:ii: 1219-22. 
6. Opelz G. Mickey MR. Terasaki PI. Prolonged survival of 
second human kidney transplants. Science 1972: 178: 
617. 
7. Opelz G. Mickey MR. Terasaki PI. Int1uence of race on 
kidney transplant survival. Transplant Proc 1977;9: 137. 
8. Opelz G. Sengar DPS. Mickey MR. Terasaki PI. Effect of 
blood transfusions on subsequent kidney transplant. 
Transplant Proc 1973:4:253-9. 
9. Takasugi M. Mickey MR. Terasaki PI. Reactivity of lym-
phocytes from normal persons on cultured tumor cells. 
Cancer Res 1973:33:2898-902. 
10. Takasugi M. Mickey MR. Terasaki PI. Studies on specific-
ity of cell-mediated immunity. J Natl Cancer Inst 1974: 
53: 1527 -38. 
11. Herberman RB. Oldham RK. Problems associated with 
study of cell-mediated immunity to human tumors by 
microcytotoxicity assays. J Natl Cancer Inst 1975:55: 
749-53. 
12. Herberman RB. Nunn ME. Lavrin DH. Natural cytotoxic 
reactivity of mouse lymphoid cells against syngeneic and 
allogeneic tumors: Distribution of reactivity and specific-
ity. Int Cancer 1975:16:216-29. 
52 THE HLA SYSTEM: BASIC BIOLOGY AND CLINICAL APPLICATIONS 
13. Herberman RB. Nunn ME. Holden HT. Lavrin DH. Natu-
ral cytotoxic reactivity of mouse lymphoid cells against 
syngeneic and allogeneic tumors. II. Characterization of 
effector cells. Int J Cancer 1975: 16:230-9. 
14. Kressling R. Klein F, Wigzell H. "Natural" killer cells in the 
mouse. I. Cytotoxic cells with specificity for mouse 
Moloney leukemia cells. Specificity and distribution ac-
cording to genotype. Eur J Immunol 1975:5: 112-7. 
15. Kressling R. Klein F. Pross H, Wigzell H. "Natural" killer 
cells in the mouse. II. CytotoxiC cells with specificity for 
mouse Moloney leukemia cells. Characteristics of the 
killer cell. Eur J Immunol 1975:5: 117 -21. 
16. Kissmeyer-Nielsen F. Olsen S, Peterson VP. Fieldborg O. 
Hyperacute rejection of kidney allografts associated with 
preexisting humoral antibodies against donor cells. lan-
cet 1966:ii:662-5. 
17. Huxley J. Soviet genetics: The real issue. Nature 1949: 
163:935-40. 
18. Soyfer VN. New light on the Lysenko era. Nature 1989; 
339:415-20. 
19. Joravsky O. Genetics besieged. review of Lysenko and the 
Tragedy oJ Soviet Science by Valery N. Soyfer (book re-
view). Nature 1994:372:284-5. 
20. Meuwissen HJ. Gatti RA, Terasaki PI. et al. Treatment of 
lymphopenic hypogammaglobulinemia and bone-mar-
row aplasia by transplantation of allogeneic marrow: 
Crucial role of histocompatibility matching. N EnglJ Med 
1969:281:691-7. 
21. Starzl TE. Porter KA. Andres G, et al. Long-term survival 
after renal transplantation in humans: With special ref-
erence to histocompatibility matching. (hymectomy. 
homograft glomerulonephritis. heterologous ALG. and 
reCipient malignancy. Ann Surg 1970: 172:437-72. 
22. Terasaki PI. Mickey MR. Histocompatibility-transplant 
correlation. reproducibility. and new matching methods. 
Transplant Proc 1971:3:1057-71. 
23. Mickey MR. Kreisler M. Albert ED. Cl a1. Analysis of HLA 
incompatibility in human renal transplants. Tissue Anti-
gens 1971:1:57-67. 
24. Terasaki PI. Cecka JM. Gjertson OW. Takemow S. High 
survival rates ofkidnev transplants from spousal and liv-
ing unrelated donors. N Engl J Med 1995:333:333-6. 
TERASAKI'S SEMINAL CONTRIBUTIONS 53 
25. Starzl TE. Eliasziw M, Gjertson M. et al. HLA and cross 
reactive antigen group (CREG) matching for cadaver kid-
ney allocation. Transplantation 1997:64:983-9l. 
26. Brent L. Immunogenetics: Histocompatibility antigens-
Genetics. structure and function. In: Brent L. ed. A his-
tory of transplantation immunology. San Diego: Aca-
demic Press. 1997:131-76. 
27. Starzl TE. Tissue matching. In: Starzl TE. ed. The puzzle 
people: Memoirs of a transplant surgeon. Pittsburgh: 
University of Pittsburgh Press. 1992: 118-24. 
28. Gibson T. Medawar PB. The fate of skin homografts in 
man. J Anat 1943:77:299-310. 
29. Medawar PB. The behavior and fate of skin autografts 
and skin homografts in rabbits. J Anat 1944:78: 176-99. 
30. Billingham RE. Brent L. Medawar PB. "Actively acquired 
tolerance" of foreign cells. Nature 1953: 172:603-6. 
31. Billingham R. Brent L. Medawar P. Quantitative studies 
on tissue transplantation immunity. III. Actively ac-
quired tolerance. Philos Trans R Soc Lond B BioI Sci 
1956:239:357-412. 
32. Main JM. Prehn RT. Successful skin homografts after the 
administration of high dosage X radiation and homolo-
gous bone marrow. J Natl Cancer Inst 1955: 15: 1023-9. 
33. Trentin JJ. Mortality and skin transplantibility in 
X-irradiated mice receiving isologous or heterologous 
bone marrow. Proc Soc Exp BioI Med 1956:92:688-93. 
34. Billingham R. Brent L. Quantitative studies on trans-
plantation immunity. IV. Induction of tolerance in new-
born mice and studies on the phenomenon of runt dis-
ease. Philos Trans R Soc Lond B BioI Sci 1959:242: 
439-77. 
35. Simonsen M. The impact on the developing embryo and 
newborn animal of adult homologous cells. Acta Pathol 
Microbiol Scand 1957:40:480-500. 
36. Mathe G. Arnie! JL. Schwarzenberg L. et al. 
Haematopoietic chimera in man after allogeneic (homol-
ogous) bone-marrow transplantation. Br Med J 1963:2: 
1633-5. 
37. Gatti RA. Meuwissen HJ. Allen HD. et a1. Immunological 
reconstitution of sex-linked lymphopenic immunological 
cietkiencv. Lancet 1968:ii: 1366-9. 
54 THE HLA SYSTEM: BASIC BIOLOGY AND CLINICAL APPLICATIONS 
38. Bach FH. Albertini RJ. Joo P. et al. Bone-marrow trans-
plantation in a patient with the Wiskott-Aldrich syn-
drome. Lancet 1968;ii: 1364-6. 
39. DeKoning J. Dooren W. Van Bekkum OW. et al. Trans-
plantation of bone marrow cells and fetal thymus in an 
infant with lymphopenic immunological deficiency. Lan-
cet 1969;i: 1223-7. 
40. Thomas ED. Allogeneic marrow grafting: A story of man 
and dog. In: Terasaki PI. edt History of transplantation: 
Thirty-five recollections. Los Angeles: UCLA Tissue 
Typing Laboratory. 1991:379-93. 
41. Starzl TE. Marchioro TL. Waddell WR. The reversal of re-
jection in human renal homo grafts with subsequent de-
velopment of homograft tolerance. Surg Gynecol Obstet 
1963: 117:385-95. 
42. Merrill JP. Murray JE. Harrison JH. et al. Successful 
homotransplantation of the kidney between non-identi-
cal twins. N EnglJ Med 1960:262:1251-60. 
43. Hamburger J. Vaysse J. Crosnier J. et al. Renal homo-
transplantation in man after radiation of the recipient. 
Am J Med 1962:32:854-71. 
44. Hamburger J. Vaysse J. Crosnier J. et al. Transplanta-
tion of a kidney between non monozygotic twins after irra-
diation of the receiver. Good function at the fourth 
month. Presse Med 1959:67:1771-5. 
45. Kuss R. Legrain M. Mathe G. et al. Homologous human 
kidney transplantation. Experience with six patients. 
Postgrad Med J 1962:38:528-31. 
46. Murray JE. Merrill JP. Dammin GJ. et al. Kidney trans-
plantation in modified recipients. Ann Surg 1962: 156: 
337-55. 
47. Murray JE. Merrill JP. Harrison JH. et al. Prolonged sur-
vival of human-kidney homografts by immunosuppres-
sive drug therapy. N Engl J Med 1963:268: 1315-23. 
48. Starzl TE. Demetris AJ. Murase N. et al. The lost chord: 
Microchimerism. Immunol Today 1996: 17:577-84. 
49. Starzl TE. Marchioro TL. Porter KA. et al. Factors deter-
mining short- and long-term survival after orthotopic 
liver homotransplantation in the dog. Surgery 1965:58: 
131-55. 
K--K~-K-~------~-
TERASAKI'S SEMINAL CONTRIBUTIONS 55 
50. Starzl TE. Demetris AJ. Trucco M. et al. Cell migration 
and chimerism after whole-organ transplantation: The 
basis of graft acceptance. Hepatology 1993: 17: 1127 -52. 
51. CaIne RY. White OJG. Thiru S. et al. Cyc1osporinAin pa-
tients receiving renal allografts from cadaver donors. 
Lancet 1978:ii: 1323-7. 
52. Calne RY. RoUes K. White OJG. et al. Cyc1osporin A ini-
tially as the only immunosuppressant in 34 recipients of 
cadaveric organs: 32 kidneys. 2 pancreases. and 2 livers. 
Lancet 1979:ii: 1033-6. 
53. Starzl TE. Weil R III. Iwatsuki S. et al. The use of 
cyc1osporin A and prednisone in cadaver kidney trans-
plantation. Surg Gynecol Obstet 1980; 151: 17-26. 
54. Starzl TE. Todo S. Fung J. et al. FK 506 for human liver. 
kidney and pancreas transplantation. Lancet 1989;ii: 
1000-4. 
55. Todo S. FungJJ. Starzl TE. et al. Liver. kidney. and tho-
racic organ transplantation under FK 506. Ann Surg 
1990:212:295-305. 
56. Starzl TE. Donner A. Eliasziw M. et al. Randomized 
trialomania? The multicenter liver transplant trials. Lan-
cet 1995:346: 1346-50. 
57. Todo S. Tzakis AG. Abu-Elmagd K. et al. Cadaveric small 
bowel and small bowel-liver transplantation in humans. 
Transplantation 1992:53:369-76. 
58. Starzl TE. Oemetris AJ. Murase N. et al. Cell migration. 
chimerism. and graft acceptance. Lancet 1992:339: 
1579-82. 
59. Starzl TE. Oemetris AJ. Trucco M. et al. Systemic 
chimerism in human female recipients of male livers. 
Lancet 1992;340:876-7. 
60. Ramsey G. Nusbacher J. Starzl TE. Lindsay GO. 
Isohemagglutinins of graft origin after ABO-unmatched 
liver transplantation. N Engl J Med 1984:311: 1167-70. 
61. Starzl TE. Zinkernagel R. Antigen localization and migra-
tion in immunity and tolerance. N Engl J Med 1998: 
339: 1905-13. 
62. Zinkernagel RM. Immunology taught by viruses. Science 
1996:271: 173-8. 
63. Zinkernagel RM. Ehl S. Aichele P. et al. Antigen localiza-
tion regulates immune responses in a dose- and time-
--"_-...-------
56 THE HLA SYSTEM: BASIC BIOLOGY AND CLINICAL APPLICATIONS 
dependent fashion: A geographical view of immune reac-
tivity. Immunol Rev 1997; 156: 199-209. 
64. Zinkernagel RM. Bachmann MF. Kundig TM. et al. On 
immunologic memory. Annu Rev Immunol 1996: 14: 
333-67. 
65. Starzl TE. Murase N. Thomson A. Demetris AJ. Stow-
away stem cells in liver contribute to immunological tol-
erance in patients receiving liver transplants. Nat Med 
1996:2: 163-5. 
66. Przepiorka D, Thomas ED, Durham DM, Fisher L. Use of 
a probe to repeat sequence of the Y chromosome for de-
tection of host cells in peripheral blood of bone marrow 
transplant recipients. Am J Clin Pathol 1991;95:201-6. 
67. Bernard C. An introduction to the study of experimental 
medicine. London: Macmillan, 1927. (Originally pub-
lished in French 1865: English translation by H.C. 
Greene.) 
